Adaptimmune Therapeutics has received FDA approval for its engineered cell therapy, Tecelra, to treat synovial sarcoma, a rare solid tumor. Tecelra, which targets the MAGE-A4 antigen, showed promising results in a Phase 2 clinical trial with a 43% overall response rate. The therapy comes with potential side effects such as cytokine release syndrome and neurotoxicity. With a list price of $727,000, Tecelra is set to become a significant asset for Adaptimmune, with projected annual sales of up to $400 million. The company is also expanding its pipeline to develop cell therapies for other types of sarcomas and solid tumors in partnership with various pharmaceutical companies.
Source link
Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors
